SUMMARY
- Beta Drugs secured ₹117 Cr from HealthQuadFund II and others through a minority share investment round.
- HealthQuad highlights Beta Drugs’ role in boosting affordability, accessibility, and market expansion in tier II and III cities.
- The company aims to become one of India’s top five oncology companies within the next five years.
Beta Drugs, a vertically integrated cancer firm, has secured ₹117 crore from HealthQuadFund II to acquire a minority share in the business. A Singapore-based investment fund and a private wealth management company also participated in the round.
Ajay Mahipal, partner at HealthQuad Capital states, “Beta Drugs, with its strong manufacturing and R&D capabilities, is poised to improve affordability in the middle- and lower-income segment, and accessibility in tier II and tier III cities in the country. We believe in the transformative potential of their new product launches, expanding export markets, and experienced management team, all of which position the company for substantial growth and value creation.”
Rahul Batra, Chairman & Managing Director (MD) of Beta Drugs stated, “Their investment and expertise will play a pivotal role in accelerating our growth journey, as we strive to position ourselves among the top five oncology companies in India over the next five years.”
Beta Drugs has a wide range of products in all of the main oncology categories, such as hormonal, supportive, targeted, and chemotherapy.
The portfolio of HealthQuad, a healthcare transformation fund, includes top businesses in the fields of artificial intelligence, data analytics, diagnostics, healthcare financing, chronic care management, and pharmaceutical distribution.
